Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 13/20 | 0.44 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.42 |
| ▸ | MTOR | P42345 | 6/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3931106 | 0.89 | ATR (0.44) | ATRATRIPPIK3CAMTORPRKDC | |
| SCHEMBL4163525 | 0.82 | HPGDS (0.45) | PIK3CAMALT1PIK3CD | |
| SCHEMBL4725857 | 0.81 | ATR (0.46) | ATRATRIPPIK3CAMTORPRKDC | |
| SCHEMBL4796500 | 0.80 | ATR (0.47) | ATRPIK3CAMTORPRKDCPIK3R1 | |
| SCHEMBL4794333 | 0.77 | ATR (0.44) | ATRATRIPPIK3CAMTORPRKDC | |
| SCHEMBL4156340 | 0.77 | HPGDS (0.48) | PIK3CAPIK3CD | |
| SCHEMBL4916252 | 0.77 | ATR (0.46) | ATRATRIPPIK3CAMTORPRKDC | |
| SCHEMBL3938224 | 0.77 | HPGDS (0.54) | PIK3CAPIK3CD | |
| SCHEMBL4781403 | 0.76 | ATR (0.51) | ATRATRIPPIK3CAMTORPRKDC | |
| SCHEMBL4916260 | 0.75 | ATR (0.46) | ATRATRIPPIK3CAMTORPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | claimed |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | claimed |
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-7504401-B2 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | ATR 3040/4885ATRIP 3288/4885PIK3CA 3659/4885 |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | ATR 3023/4885ATRIP 3263/4885PIK3CA 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.